Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AQX-1125 DDI with Oral Contraceptives
NCT03478020Phase 1Completed
- Sponsor
- Aquinox Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rosiglitazone in interstitial cystitis (IC) and bladder pain syndrome (BPS), sponsored by Aquinox Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration of COC taken with AQX-1125 at 8 Weeks, Time to attain maximum observed plasma concentration of COC taken with AQX-1125 at 8 Weeks and 3 more. Started Nov 2017; status: completed.
02
Drugs
rosiglitazone
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT03478020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03478020.